Week in Review: Suzhou's Adagene to Stage $125 Million IPO on NASDAQ

Deals and Financings:   Suzhou's Adagene plans to raise up to $125 million in a US IPO on the NASDAQ Exchange to support its portfolio of immunotherapy candidates; Elpiscience of Shanghai acquired China rights to a bispecific antibody being developed by US-based TRIGR in a $117 million deal; Suzhou Sinovent completed a pre-IPO financing of at least $30 million to develop its 12 biologic products; Beijing 's Immunotech Biopharm in-licensed China rights to a T-cell receptor therapy for renal cell cancer from T-Cure Bio of California; Neurophth Therapeutics of Wuhan partnered with Delaware 's AAVnerGene to develop adeno-associated virus capsids for ophthalmic gene therapies; TenNor Therapeutics ( Suzhou ) will collaborate with Janssen, using its drug conjugation platform to discover new therapies for mycobacteria diseases; COVID-19 Pandemic   Sinovac Biotech of Beijing will expand production of CoronaVac, the company's inactivated COVID-19 vaccine, to produce two billion doses this year; Jemincare Group of Nanchang started a China Phase I clinical trial of an anti-SARS-CoV-2 neutralizing antibody; Trials and Approvals   Seneca Biopharma, a Maryland-Suzhou company, reported mixed results from a China trial of its stem cell treatment for ischemic stroke; Suzhou 's Gracell Biotech will start a China trial of its FasTCAR cell therapy in adult patients with B-cell acute lymphoblastic leukemia; EdiGene, a Beijing company, was approved to start China clinical trials of its gene-edited stem cell therapy to treat transfusion dependent β-thalassemia. Stock Symbols: (HK: 6978) (NSDQ: SNCA) (NSDQ: GRCL) Share this with colleagues: // //